Media headlines about Interpace Diagnostics Group (NASDAQ:IDXG) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the business services provider an impact score of 46.3023783142322 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Notable Stocks to Watch: US Bancorp,(NYSE: USB),EQT Corporation, (NYSE: EQT), Interpace Diagnostics Group, Inc … – Money making news (press release) (stocknews.pro)
- Quarterly Gainer: Interpace Diagnostics Group, Inc. (IDXG) stock performed 82.35% – Street Observer (press release) (streetobserver.com)
- Atento (ATTO) & Interpace Diagnostics Group (IDXG) Head to Head Contrast (americanbankingnews.com)
- Contrasting Interpace Diagnostics Group (IDXG) & WageWorks (WAGE) (americanbankingnews.com)
- Interpace Diagnostics Announces Increased Reimbursement for ThyGenX® (finance.yahoo.com)
Shares of Interpace Diagnostics Group (IDXG) opened at 1.48 on Tuesday. The company has a 50 day moving average price of $1.51 and a 200 day moving average price of $1.59. Interpace Diagnostics Group has a 52 week low of $0.07 and a 52 week high of $14.25. The company’s market cap is $32.80 million.
Interpace Diagnostics Group (NASDAQ:IDXG) last announced its quarterly earnings data on Thursday, August 10th. The business services provider reported ($0.65) earnings per share for the quarter. Interpace Diagnostics Group had a negative net margin of 37.08% and a negative return on equity of 32.06%. The firm had revenue of $3.86 million for the quarter.
IDXG has been the topic of several research reports. ValuEngine upgraded shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. Maxim Group initiated coverage on Interpace Diagnostics Group in a report on Tuesday, August 15th. They issued a “buy” rating and a $5.00 target price on the stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Interpace Diagnostics Group (NASDAQ:IDXG) Stock Price” was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/interpace-diagnostics-group-idxg-earns-daily-media-sentiment-rating-of-0-15/1698170.html.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.
Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with our FREE daily email newsletter.